GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » Earnings per Share (Diluted)

Hemagen Diagnostics (Hemagen Diagnostics) Earnings per Share (Diluted) : $-0.06 (TTM As of Sep. 2012)


View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics Earnings per Share (Diluted)?

Hemagen Diagnostics's Earnings per Share (Diluted) for the three months ended in Sep. 2012 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2012 was $-0.06.

Hemagen Diagnostics's EPS (Basic) for the three months ended in Sep. 2012 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2012 was $-0.06.

Hemagen Diagnostics's EPS without NRI for the three months ended in Sep. 2012 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2012 was $-0.06.


Hemagen Diagnostics Earnings per Share (Diluted) Historical Data

The historical data trend for Hemagen Diagnostics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics Earnings per Share (Diluted) Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -0.05 -0.01 -0.06 -0.06

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.01 -0.01

Competitive Comparison of Hemagen Diagnostics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Hemagen Diagnostics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's PE Ratio falls into.



Hemagen Diagnostics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Hemagen Diagnostics's Earnings Per Share (Diluted) for the fiscal year that ended in Sep. 2012 is calculated as

Diluted Earnings Per Share (A: Sep. 2012 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.907-0)/15.496
=-0.06

Hemagen Diagnostics's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2012 is calculated as

Diluted Earnings Per Share (Q: Sep. 2012 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.163-0)/15.500
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Hemagen Diagnostics  (OTCPK:HMGN) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Hemagen Diagnostics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.
Executives
Howard F Curd director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines